Would you ever consider taking diet pills to help you lose weight? According to a ... the appetite suppressant phentermine marketed as Duromine and Ionamin, was officially withdrawn in Britain ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Behind the hype: Are these weight-loss drugs worth it?(File Photo) In an interview with HT Lifestyle, Dr Shobha Subramanian-Itolikar, Consultant Physician at Fortis Hospital in Mulund, shared ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Weight loss drugs like Wegovy, Ozempic, and Mounjaro show transformative effects in obesity, improving heart health and reducing dementia risks. However, studies reveal significant muscle and bone ...

We have made this January "wellness month" here on the ABC7 and we are tackling a hot topic - weight loss drugs. The pros, cons and who can benefit.

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular drugs.